All Articles

For those with Primary Sclerosing Cholangitis, a cureless liver disease, a new drug shows potential to slow its relentless march. Here's what it means.

Habanos S.A. unveils the Diplomáticos Cancilleres in Sofia, a strategic launch blending Cuban heritage with a bold push into Eastern Europe's market.

Quebec pioneers a solution to the growing tide of vape e-waste, but can this new model for recycling cannabis devices be replicated across the nation?

Promising survival data and a novel biomarker strategy from BriaCell could reshape the metastatic breast cancer treatment and investment landscape.

The world's top animal health firm is targeting cancer and heart disease in pets, deploying a multi-billion dollar R&D strategy to lead the next era.

A new global study debunks the myth of the dying CMO, revealing a new taxonomy of adaptive leaders built for turbulence, change, and complexity.

CTW Cayman is bypassing app stores with HTML5 games. Its new Crayon Shinchan title reveals a disruptive strategy leveraging anime IP for global dominance.

TrustCommerce and Qure4u's new AI-powered payment platform aims to fix a broken system, easing patient stress and boosting provider revenue. Is this the future?

As banks retreat from commercial real estate, Nuveen's oversubscribed debt fund signals a major shift toward alternative lenders in the value-add space.

The acquisition unites AI-powered web content with social media expertise, signaling a major shift toward integrated global marketing platforms.

A new car wash opening in Arizona reveals a global strategy to merge fuel, retail, and services, creating powerful consumer ecosystems and reshaping markets.

Two mining giants are setting aside decades of competition to unlock critical minerals in a historic partnership that could reshape Canada's supply chain.

With animal trials failing 90% of the time, a new consortium aims to standardize organoid models, promising faster, cheaper, and more human-relevant drug discovery.

The #2 U.S. outpatient imaging firm is going public to pay down debt. Is it a picture of health for investors or a risky PE-driven exit play?

Parisian biotech Egle Therapeutics begins human trials for a novel drug designed to rebalance the immune system, offering new hope for millions with eczema.

Gilat Satellite Networks' new defense contract for a transportable ground terminal signals a strategic shift into the booming geospatial intelligence market.

With major funding from industry veterans, AnChain.AI is deploying agentic AI to fight fraud. This isn't just tech; it's a new paradigm for digital trust.

Award-winning Hi3 gene-editing promises to slash maize breeding times, boosting yields and positioning Origin Agritech for major commercial breakthroughs.

In a field full of speculative bots, IODJ's new Insight Engine offers traders market analysis, not signals. Is this the future of responsible crypto?

Amid global headwinds, PE firms deploy innovative strategies to fuel deals, with a major focus on healthcare and technology as the market slowly recovers.